FDA Aims For Transparency In Releasing New Risk-Based Site Selection Model For Determining Who Is Inspected Next
Executive Summary
US FDA explains new risk-based model for selecting manufacturing sites for inspection in US and abroad. By releasing information about the model, FDA aims to shed some transparency in its decision-making process.
You may also be interested in...
US FDA’s Streamlined Drug Approval Packages Shine Less Light On Sponsor Interactions
CDER is no longer proactively posting mid- and late-cycle meeting minutes and certain correspondence with sponsors for new drug and biologic approvals; drugs center says it is focused on ensuring the most scientifically meaningful information is prioritized and posted in a timely manner, but some observers say the change raises transparency concerns.
US FDA’s Streamlined Drug Approval Packages Shine Less Light On Sponsor Interactions
CDER is no longer proactively posting mid- and late-cycle meeting minutes and certain correspondence with sponsors for new drug and biologic approvals; drugs center says it is focused on ensuring the most scientifically meaningful information is prioritized and posted in a timely manner, but some observers say the change raises transparency concerns.
US FDA's Inspection Decisions To Be Swayed By Facility "History" With Foreign Regulators
Leveraging foreign surveillance inspections could help FDA ensure more sites are inspected more often.